Table 4.
Results of univariate analysis for resolution of pain in 154 patients according to intention to treat after eliminating 34 patients who discontinued the study
| Pain resolved | Pain persisted | P | |
|---|---|---|---|
| n (% or ±SD) | n (% or ±SD) | ||
| Age | 48.5 (11.7) | 52.02 (13.3) | 0.093 |
| Male | 53 (64) | 30 (36) | 0.674 |
| Female | 43 (61) | 28 (39) | |
| 40 days | 43 (58) | 32 (42) | 0.212 |
| 80 days | 53 (68) | 26 (32) | |
| Duration of symptoms weeks | 12.45 (25.9) | 14.72 (11.5) | 0.528 |
| Fibrosis | 51 (55) | 42 (45) | 0.018 |
| No fibrosis | 45 (74) | 16 (26) | |
| Exposed sphincter | 72 (62) | 45 (38) | 0.716 |
| No exposed sphincter | 24 (65) | 13 (35) | |
| Skin tag | 51 (65) | 28 (35) | 0.560 |
| No skin tag | 45 (60) | 30 (40) | |
| Hypertrophied anal papilla | 40 (60) | 26 (40) | 0.701 |
| No hypertrophied anal papilla | 56 (64) | 32 (36) | |
| Fissure gravity score | 2.11 (0.78) | 2.40 (8.37) | 0.036 |
| VAS at defecation | 7.380 (1.729) | 7.681 (1.889) | 0.3139 |
| MRP mmHga | 98.931 (20.063) | 109.77 (26.468) | 0.0128 |
| Grade 1 | 24 (65) | 13 (35) | 0.1552# |
| Grade 2 | 37 (80) | 9 (20) | 0.0009¥ |
| Grade 3 | 35 (50) | 36 (50) | |
| Similar past episodes | 49 (65) | 26 (35) | 0.5075 |
| No past episodes | 47(59) | 32 (41) |
VAS visual analogue score, MRP maximum resting pressure
#Grade 1 vs. Grade 3; ¥Grade 2 vs. Grade 3
aMRP was available in 118 of 154 patients